These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 22305694)

  • 1. Aspirin and angioplasty.
    Pentecost MJ
    J Am Coll Radiol; 2012 Feb; 9(2):95. PubMed ID: 22305694
    [No Abstract]   [Full Text] [Related]  

  • 2. A review of international pharmacoeconomic models assessing the use of aspirin in primary prevention.
    Annemans L; Wittrup-Jensen K; Bueno H
    J Med Econ; 2010; 13(3):418-27. PubMed ID: 20632895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin for the primary prevention of cardiovascular disease in women: a cost-utility analysis.
    Pignone M; Earnshaw S; Pletcher MJ; Tice JA
    Arch Intern Med; 2007 Feb; 167(3):290-5. PubMed ID: 17296886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischemic burden, treatment allocation, and outcomes in stable coronary artery disease.
    Farzaneh-Far A; Borges-Neto S
    Circ Cardiovasc Imaging; 2011 Nov; 4(6):746-53. PubMed ID: 22086945
    [No Abstract]   [Full Text] [Related]  

  • 5. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
    Lindgren P; Stenestrand U; Malmberg K; Jönsson B
    Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of aspirin treatment in the primary prevention of cardiovascular disease events in subgroups based on age, gender, and varying cardiovascular risk.
    Greving JP; Buskens E; Koffijberg H; Algra A
    Circulation; 2008 Jun; 117(22):2875-83. PubMed ID: 18506010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential economic impact of increasing low dose aspirin usage on CVD in the US.
    Manson SC; Benedict A; Pan F; Wittrup-Jensen KU; Fendrick AM
    Curr Med Res Opin; 2010 Oct; 26(10):2365-73. PubMed ID: 20738228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
    Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of prevention on reducing the burden of cardiovascular disease.
    Kahn R; Robertson RM; Smith R; Eddy D
    Circulation; 2008 Jul; 118(5):576-85. PubMed ID: 18606915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Health economic evaluation of low-dose acetylsalicylic acid in the primary prevention of cardiovascular disease].
    Lamotte M; Piñol C; Brotons C; Annemans L; Guardiola E; Evers T; Kubin M
    Rev Esp Cardiol; 2006 Aug; 59(8):807-15. PubMed ID: 16938230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Costs of interventional cardiac procedures.
    Mark DB
    J Interv Cardiol; 1994 Aug; 7(4):369-78. PubMed ID: 10151067
    [No Abstract]   [Full Text] [Related]  

  • 12. Transradial coronary angiography and percutaneous intervention in the era of health care reform, cost containment, and patient-centered care.
    Escárcega RO; Bashir R; George JC
    J Invasive Cardiol; 2011 Sep; 23(9):383-5. PubMed ID: 21891811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of the resource utilization between simultaneous strategy and staged strategy to treat two-vessel coronary artery disease by percutaneous coronary intervention.
    Sakakura K; Ako J; Wada H; Kubo N; Momomura S
    J Invasive Cardiol; 2011 Nov; 23(11):454-9. PubMed ID: 22045077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
    Shaker M; Lobb A; Jenkins P; O'Rourke D; Takemoto SK; Sheth S; Burroughs T; Dykewicz MS
    J Allergy Clin Immunol; 2008 Jan; 121(1):81-7. PubMed ID: 17716716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost analysis of percutaneous coronary intervention and coronary artery bypass grafting in Japan and USA].
    Chino M; Sasaki T
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():632-7. PubMed ID: 12735043
    [No Abstract]   [Full Text] [Related]  

  • 17. Does certificate of need affect cardiac outcomes and costs?
    Ho V
    Int J Health Care Finance Econ; 2006 Dec; 6(4):300-24. PubMed ID: 17340175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ars longa, vita brevis.
    Di Mario C
    JACC Cardiovasc Interv; 2009 Jun; 2(6):487-8. PubMed ID: 19539250
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost-effectiveness of proton pump inhibitor cotherapy in patients taking long-term, low-dose aspirin for secondary cardiovascular prevention.
    Saini SD; Schoenfeld P; Fendrick AM; Scheiman J
    Arch Intern Med; 2008 Aug; 168(15):1684-90; discussion 1691. PubMed ID: 18695083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of occupational circulatory disease.
    Leigh JP; Schnall P
    Occup Med; 2000; 15(1):257-67, v. PubMed ID: 10702089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.